Abstract
Fibrosis is a common pathological feature observed in muscle from patients with Duchenne muscular dystrophy and in mdx diaphragm. The purpose of this study was to determine whether pentoxifylline (PTX) treatment for 4 weeks (16 mg/kg/day) could significantly attenuate the process of fibrosis in diaphragm muscle from mdx mice. PTX treatment had no impact on in vitro diaphragm muscle contractile function. In addition, diaphragm muscle hydroxyproline concentration and the level of type I and III collagen and TGF-beta1 mRNA were unaffected by PTX treatment. These findings do not support the use of PTX as an antifibrotic drug for the treatment of muscular dystrophy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Collagen Type I / genetics
-
Collagen Type III / genetics
-
Diaphragm / pathology*
-
Diaphragm / physiology
-
Disease Models, Animal
-
Enzyme Inhibitors / pharmacology*
-
Fibrosis
-
Hydroxyproline / metabolism
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Inbred mdx
-
Muscle Contraction / drug effects
-
Muscular Dystrophy, Animal / drug therapy*
-
Muscular Dystrophy, Animal / pathology
-
Muscular Dystrophy, Duchenne / drug therapy*
-
Muscular Dystrophy, Duchenne / pathology
-
Pentoxifylline / pharmacology*
-
RNA, Messenger / analysis
-
Transforming Growth Factor beta / genetics
-
Transforming Growth Factor beta1
-
Treatment Failure
Substances
-
Collagen Type I
-
Collagen Type III
-
Enzyme Inhibitors
-
RNA, Messenger
-
Tgfb1 protein, mouse
-
Transforming Growth Factor beta
-
Transforming Growth Factor beta1
-
Hydroxyproline
-
Pentoxifylline